Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 12 of 12 publications.
Skip to main content
Weber J, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, van Akkooi ACJ, Menzies AM, Long GV, Taylor AM, Haanen J, Zijlker LP, Davis KL, Karanth S, Norton D, Connolly L. Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma. Oncologist. 2025 Mar 10;30(3):oyae289. doi: 10.1093/oncolo/oyae289
Bai S, Tornello SL, Mogle JA, Feinberg ME. Daily implementation of health-protective behaviors and family life during the early months of the COVID-19 pandemic. Fam Process. 2024 Mar;63(1):428-42. doi: 10.1111/famp.12870.
Tam S, Neslund-Dudas C, Barrett AM, Barrow LCJ, Fridman I, Kinlaw AC, Puviindran P, Royce TJ, Smith AB, Stein JN, Wood WA, Lafata JE. The perceived usability of virtual visits among black adults' receiving oncology care: a qualitative analysis. Oncologist. 2024 Feb 2;29(2):e237-47. doi: 10.1093/oncolo/oyad260
Le Y, Mogle JA, Feinberg ME. Trajectories of parent and child well-being across the pandemic year: role of financial strain, social distancing, and COVID-19 prevalence. Fam Process. 2023 Sep;62(3):1134-46. doi: 10.1111/famp.12823
Bergerot C, Young Rha S, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Lyun Lee J, Sunela K, Ciuleanu T, Heng D, Glen H, Wang J, Bennett L, Pan J, O'Hara K, Puente J. Health-related quality of life outcomes with two different starting doses of lenvatinib in combination with everolimus for previously treated renal cell carcinoma. Oncologist. 2023 Jan 18;28(1):59-71. doi: 10.1093/oncolo/oyac142
Feinberg ME, Gedaly L, Mogle J, Hostetler ML, Cifelli JA, Tornello SL, Lee JK, Jones DE. Building long-term family resilience through universal prevention: 10-year parent and child outcomes during the COVID-19 pandemic. Fam Process. 2022 Mar;61(1):76-90. doi: 10.1111/famp.12730
Jenkins AIC, Fredman SJ, Le Y, Mogle JA, McHale SM. Religious coping and gender moderate trajectories of marital love among black couples. Fam Process. 2022 Mar;61(1):312-25. doi: 10.1111/famp.12645
Garcia-Albeniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. Prospective biomarker study in advanced RAS wild‐type colorectal cancer: POSIBA Trial (GEMCAD 10‐02). Oncologist. 2019 Nov;24(11):e1115-22. doi: 10.1634/theoncologist.2018-0728
Postmus D, Richard S, Bere N, van Valkenhoef G, Galinsky J, Low E, Moulon I, Mavris M, Salmonsson T, Flores B, Hillege H, Pignatti F. Individual trade‐offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma. Oncologist. 2018 Jan;23(1):44-51. doi: 10.1634/theoncologist.2017-0257
Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.
Sherrill B, Amonkar MM, Sherif B, Maltzman J, O'Rourke L, Johnston S. Quality of life in hormone receptor–positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist. 2010 Sep 1;15(9):944-53.
Sherrill EH, Amonkar MM, Sherif BN, Maltzman J, O'Rourke L, Johnston S. Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist. 2010;15(9):944-53.